Myelocyte

(redirected from Myeloid cells)
Also found in: Dictionary, Thesaurus, Medical.

myelocyte

[′mī·ə·lə‚sīt]
(histology)
A motile precursor cell of blood granulocytes found in bone marrow.

Myelocyte

 

one of the types of cells in the hematopoietic tissue of the red bone marrow in vertebrate animals and in man. They are formed from hemocytoblasts and pass through the promyelocyte stage. Granular leukocytes, or granulocytes, develop from myelocytes. The nuclei of myelocytes are round or bean-shaped and less compact than in mature leukocytes; the cytoplasm is weakly basophilic. Myelocytes do not normally enter the bloodstream, but in certain pathological conditions, such as leukemia, they may appear in the blood.

References in periodicals archive ?
Evaluation and validation of the detection of soluble triggering receptor expressed on myeloid cells 1 by enzyme-linked immunosorbent assay.
A20 (Tnfaip3) Deficiency in myeloid cells protects against influenza A virus infection.
Transforming growth factor-[beta] production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic t lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence," Journal of Experimental Medicine, vol.
Myeloid sarcoma is a mass of immature myeloid cells that is seen more often in children than adults without gender predominance.
Therefore, a high index of suspicion and recognition of immature myeloid cells associated with the reactive cells are required to establish the diagnosis of myeloid sarcoma.
Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia.
Because myeloid cells copiously express MPO and because halogenated DNA may induce both genetic and epigenetic changes that contribute to carcinogenesis, halogenative stress may account for benzene-induced bone marrow disorders and myeloid leukemia.
In this study researchers tested a working model in which free fatty acids (FFA) activated inflammasome dependent IL-1P secretion from myeloid cells, this IL-1P release which then impaired the physiological functions of insulin in insulin target organs.
With the increase of tyrosine kinase activity there is a loss of apoptosis, loss of bone marrow adhesion with an increased release of myeloid cells that leave the bone marrow too soon.
PI-3 kinase gamma operates like a "switch" that allows myeloid cells to invade tumours.